Why the study?
Does azilsartan improve blood pressure reduction in patients with hypertension compared to other ARBs or ACE inhibitors?
Does azilsartan improve blood pressure reduction in patients with hypertension compared to other ARBs or ACE inhibitors?
Azilsartan is a potent ARB that provides superior blood pressure reduction compared to several other ARBs and ACE inhibitors, with a comparable safety profile.
Azilsartan may offer potency advantages in hypertension; leaves open whether structural novelty improves outcomes versus established ARBs.
Hypertension is attributed to be one of the major risk factors in the pathophysiology of ischemic heart disease, stroke, heart failure and renal dysfunction. Angiotensin receptor blockers (ARBs) are one of the first line drugs recommended for clinical use in hypertension by JNC 8. Azilsartan is the recent addition to this family of ARBs and is perceived as one of the potent antihypertensive drugs today. Azilsartan was developed by replacing the tetrazole ring in candesartan with a 5 member oxo-oxadiazole ring. In India Azisartan was recently approved by DCGI in December 2016 for use in hypertension. In various randomized, double blind clinical studies Azilsartan was found to be to be superior in terms of clinical efficacy over other ARBs like Candesartan, Olmesartan and Valsartan and angiotensin converting enzyme inhibitor like Ramipril. In terms of safety profile Azilsartan appears to be equivalent to the currently available ARBs. Azilsartan due to its superior efficacy and comparative safety profile appear to be a new addition to the armamentarium in the treatment of hypertension.
No takes yet. Share an insight, caveat, or question.
Hiremath et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: